Article Text

PDF
Original article
Human papillomavirus genotype distribution among Cameroonian women with invasive cervical cancer: a retrospective study
  1. David Pirek1,
  2. Patrick Petignat1,
  3. Pierre Vassilakos2,
  4. Jolanta Gourmaud3,
  5. Jean-Claude Pache3,
  6. Laura Rubbia-Brandt3,
  7. Zacharie Sando4,
  8. Thomas Alexander McKee3,
  9. Liza Ho3
  1. 1Department of Obstetrics and Gynecology, University Hospitals of Geneva, Geneva, Switzerland
  2. 2Geneva Foundation for Medical Education and Research, Geneva, Switzerland
  3. 3Department of Clinical Pathology, University Hospitals of Geneva, Geneva, Switzerland
  4. 4Department of Clinical Pathology, Gyneco-Obstetric and Pediatric Hospital, Yaoundé, Cameroon
  1. Correspondence to David Pirek, Department of Obstetrics and Gynecology, University Hospitals of Geneva 1211, Switzerland; David.Pirek{at}hcuge.ch

Abstract

Objectives We determined the human papillomavirus (HPV) types present in invasive cervical cancer (ICC) of women in Cameroon in order to estimate the potential efficacies of HPV prophylactic vaccines.

Methods This is a retrospective study using 181 formalin-fixed paraffin-embedded cervical tissue samples of ICC collected from the Institute of Pathology, Gyneco-Obstetric and Pediatric Hospital, Yaoundé, Cameroon. HPV was detected by PCR using modified GP5+/GP6+ (MGP) primers. Genotyping was performed by reverse-blot hybridisation, which allowed the detection of 9 of the 14 high-risk HPV types.

Results Of the 181 samples, 91.7% were squamous cell carcinomas and 6.6% were adenocarcinomas. Counting all the single and multiple infections, the three most common high-risk types in descending order were HPV16 (88%), HPV45 (32%) and HPV18 (14.8%). 54.9% of cases were infected with a single HPV type and 45.1% had two or more HPV infections.

Conclusions The frequencies of HPV16, HPV45 and multiple infections are all higher than previously reported. These observations have significant implications on the consideration of vaccination strategies because each vaccine has different duration and efficacies in cross-protection of different HPV types. The method used proved to be sensitive and cost-efficient for retrospective studies where fresh materials are not available.

  • HPV
  • INFECTION
  • CERVICAL NEOPLASIA
  • DNA AMPLIFICATION
  • AFRICA

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.